Loading, Please Wait...
BOSTON, May 02, 2019 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Nabriva Therapeutics plc (“Nabriva” or the “Company”) (NASDAQ: NBRV) and certain of its officers and directors violated federal securities laws.
On April 30, 2019, Nabriva disclosed that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") for the Company's New Drug Application ("NDA") seeking marketing approval of CONTEPO™ for the treatment of complicated urinary tract infections. Nabriva advised investors that "[t]he CRL requests that Nabriva address issues related to facility inspections and manufacturing deficiencies at one of Nabriva's contract manufacturers prior to the FDA approving the NDA."
On this news, Nabriva's stock price fell $0.82 per share, or 27.42%, to close at $2.17 per share on May 1, 2019.
We are investigating whether Nabriva failed to inform investors of these manufacturing deficiencies and inspection issues and the possibility of filing a lawsuit against Nabriva. If you have purchased or otherwise acquired Nabriva securities and have questions about your legal rights, or possess information relevant to this investigation, you are encouraged to contact attorney Dan DeMaria at (888) 868-2385, by email at firstname.lastname@example.org, or by visiting http://shareholder.law/cases/?case=nabriva.
Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.
This notice may constitute attorney advertising.
BLOCK & LEVITON LLP
(617) 398-5660 phone
260 Franklin Street, Suite 1860
Boston, MA 02110
SOURCE Block & Leviton LLP